Brief: Ironwood Pharmaceuticals Provides Clinical And Regulatory Update On Apraglutide
14/04/2025 12:07
April 14 (Reuters) - Ironwood Pharmaceuticals Inc IRWD.O: IRONWOOD PHARMACEUTICALS PROVIDES CLINICAL AND REGULATORY UPDATE ON APRAGLUTIDE IRONWOOD PHARMACEUTICALS INC - ENGAGES GOLDMAN SACHS TO EXPLORE STRATEGIC ALTERNATIVES IRONWOOD PHARMACEUTICALS INC - REQUIRES CONFIRMATORY PHASE 3 TRIAL FOR APRAGLUTIDE APPROVAL IRONWOOD PHARMACEUTICALS INC - TO WORK WITH FDA ON CONFIRMATORY PHASE 3 TRIAL DESIGN Source text: ID:nBw4hPKwZa Further company coverage: IRWD.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Ironwood Pharmaceuticals
See all newsBrief: Ironwood Pharmaceuticals Appoints Tammi Gaskins As Chief Executive Officer
Ironwood Pharmaceuticals, Inc. reports results for the quarter ended June 30 - Earnings Summary
Ironwood Q2 revenue rises 33%
Brief: Ironwood Pharmaceuticals Repaid In Full $200 Million 1.5% Convertible Senior Notes Due 2026
Brief: FDA Approves Use Of Linzess In Pediatric Patients Aged 2 & Older With Functional Constipation